WELCOME TO The PHARMACEUTICAL REPORT
Introducing EU Annex 1: Understanding the Newest Regulatory Requirements
July 1, 2023
I'm For Real
Enter your details once to access all our information and resources
As people age, they often develop chronic diseases and rely on synthetic prescription drugs for relief. Unfortunately, these medicines usually only mask symptoms.
whitePaper | March 28, 2023
About 70% of new chemical entities (NCEs) are highly insoluble.1 It’s a fact that troubles small biotechnology companies and other drug manufacturers. Indeed, insoluble drugs present a wide range of challenges during development and, if not addressed, can ultimately render drugs ineffective in patients.
whitePaper | January 23, 2023
Investments in biopharmaceutical (biopharma) research and development (R&D) continue to fuel innovation and shape the future of health. However, this year’s analysis demonstrates that despite impressive examples of innovative products the step-change in improved productivity seen in 2021 has not continued.
whitePaper | April 7, 2021
In less than a week, in the face of a pandemic, the pharmaceutical sales model changed forever. In-person healthcare provider (HCP) visits came to a screeching halt and brand marketers scrambled to find ways to educate and engage these providers remotely. While the pandemic may have taken us by surprise, we should acknowledge that, even before the pandemic, pharmaceutical sales teams faced significant challenges.
One solution for these challenges is to engage HCPs – virtually.
whitePaper | July 11, 2022
The expansion in the development and manufacturing
of highly potent active pharmaceutical ingredients
(HPAPIs) and complex active pharmaceutical
ingredients (APIs) has grown tremendously as demands
in healthcare to bring newer therapies to market quicker
whitePaper | December 13, 2022
Viral vectors are a critical part of the advanced therapies
supply chain as they are used to introduce the gene of
interest, whether that’s into a cell intended for therapeutic
gene transfer or for direct viral-mediated gene transfer into
whitePaper | July 8, 2022
Particulates are ubiquitous in parenteral drug products and remain a concern throughout their development and production1–3. These particles must be monitored to satisfy.
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the
community for FREE